Show simple item record

Use of Integrated SPECT/CT Imaging for Tumor Dosimetry in I-131 Radioimmunotherapy: A Pilot Patient Study

dc.contributor.authorDewaraja, Yuni K.en_US
dc.contributor.authorWilderman, Scott J.en_US
dc.contributor.authorKoral, Kenneth F.en_US
dc.contributor.authorKaminski, Mark S.en_US
dc.contributor.authorAvram, Anca M.en_US
dc.date.accessioned2010-10-14T14:20:34Z
dc.date.available2010-10-14T14:20:34Z
dc.date.issued2009-08en_US
dc.identifier.citationDewaraja, Yuni K.; Wilderman, Scott J.; Koral, Kenneth F.; Kaminski, Mark S.; Avram, Anca M. (2009/08). "Use of Integrated SPECT/CT Imaging for Tumor Dosimetry in I-131 Radioimmunotherapy: A Pilot Patient Study." Cancer Biotherapy & Radiopharmaceuticals, 24(4): 417-426 <http://hdl.handle.net/2027.42/78152>en_US
dc.identifier.issn1084-9785en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/78152
dc.description.abstractAbstract Integrated systems combining functional (single-photon emission computed tomography; SPECT) imaging with anatomic (computed tomography; CT) imaging have the potential to greatly improve the accuracy of dose estimation in radionuclide therapy. In this article, we present the methodology for highly patient-specific tumor dosimetry by utilizing such a system and apply it to a pilot study of 4 follicular lymphoma patients treated with I-131 tositumomab. SPECT quantification included three-dimensional ordered-subset expectation-maximization reconstruction and CT-defined tumor outlines at each time point. SPECT/CT images from multiple time points were coupled to a Monte Carlo algorithm to calculate a mean tumor dose that incorporated measured changes in tumor volume. The tumor shrinkage, defined as the difference between volumes drawn on the first and last CT scan (a typical time period of 15 days) was in the range 5%-49%. The therapy-delivered mean tumor-absorbed dose was in the range 146-334cGy. For comparison, the therapy dose was also calculated by assuming a static volume from the initial CT and was found to underestimate this dose by up to 47%. The agreement between tracer-predicted and therapy-delivered tumor-absorbed dose was in the range 7%-21%. In summary, malignant lymphomas can have dramatic tumor regression within days of treatment, and advanced imaging methods allow for a highly patient-specific tumor-dosimetry calculation that accounts for this regression.en_US
dc.format.extent442114 bytes
dc.format.extent3100 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherMary Ann Liebert, Inc.en_US
dc.titleUse of Integrated SPECT/CT Imaging for Tumor Dosimetry in I-131 Radioimmunotherapy: A Pilot Patient Studyen_US
dc.typeArticleen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid19694576en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/78152/1/cbr.2008.0568.pdf
dc.identifier.doi10.1089/cbr.2008.0568en_US
dc.identifier.sourceCancer Biotherapy & Radiopharmaceuticalsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.